

PRESS-RELEASE – FOR IMMEDIATE RELEASE

Ewopharma and Purpose Pharma Announce a Strategic Partnership for the Commercialization of Attrogy in Selected Central and Eastern European Countries

Schaffhausen, Switzerland, 12 October 2026 – Ewopharma is pleased to announce that it has entered into a strategic collaboration with Purpose Pharma for the commercialization of Attrogy® (diflunisal) in selected Central and Eastern European (CEE) countries. The partnership aims to expand patient access to this important therapy to support the successful introduction and long-term development of Attrogy®.

Attrogy® received approval from the European Medicines Agency in July 2025 for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. This disease is a severe, progressive, and potentially fatal condition that causes damage to peripheral nerves and can significantly impair patients' mobility, quality of life and independence.

Under the terms of the agreement, Ewopharma will contribute its expertise in CEE markets, as well as its established capabilities in market access, commercialization, and medical affairs. Purpose Pharma will support the collaboration with its scientific leadership and product expertise. The partnership reflects a shared ambition to support patients living with rare and progressive neurological disorders.

"We are delighted to partner with Purpose Pharma and add Attrogy® to our growing specialty care portfolio," said Reto Schaberl, Director Business Development & Specialty Pharma at Ewopharma. "The collaboration with Purpose Pharma reflects our commitment to improving access to specialized therapies for patients living with rare diseases. Attrogy is an excellent strategic fit with our neurology focus and further strengthens our position in this important therapeutic area."

Jonas Hansson, CEO of Purpose Pharma, added: "With Ewopharma, we have gained an experienced and highly respected partner with a strong presence in Central and Eastern Europe. Together, we aim to expand access to treatment options for patients living with hATTR amyloidosis."

For further information, please contact:

Reto Schaberl
Director Business Development & Specialty Pharma
Ewopharma AG
E-Mail: r.schaberl@ewopharma.com

About Ewopharma AG

Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical marketing company focused on Central Eastern Europe and Switzerland. With more than 60 years of presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialisation of ethical pharmaceutical and consumer health products. Further information is available at www.ewopharma.com.

About Purpose Pharma

Purpose Pharma is a European pharmaceutical company based in Stockholm (Sweden) focused on the development and commercialization of novel rare disease and specialty care products in areas of high unmet medical need. For more information about Purpose Pharma, please visit www.purposepharma.com.

PR contact: jonas.hansson@purposepharma.com